Lilly and Merck expand immuno-oncology collaboration

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Eli Lilly and Co. announced the expansion of an existing immuno-oncology collaboration with to add a new study of Lilly’s Lartruvo (olaratumab) with Keytruda (pembrolizumab) in patients with previously treated advanced or metastatic soft tissue sarcoma.

FDA recently granted accelerated approval for Lartruvo (olaratumab injection, 10 mg/mL), in combination with doxorubicin, for the treatment of adults with STS with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.

Lartruvo (olaratumab injection, 10 mg/mL), in combination with doxorubicin, also recently received conditional marketing authorization from the European Medicines Agency for the treatment of adults with advanced STS not amenable to curative treatment with surgery or radiotherapy and who have not been previously treated with doxorubicin.

Lilly is the sponsor of the phase 1 study and enrollment is expected to begin mid-2017. Other ongoing trials between Lilly and Merck, through a subsidiary, include:

  • Studies of pemetrexed (plus carboplatin) and pembrolizumab in first-line nonsquamous non-small cell lung cancer, including a phase III study that is currently enrolling patients;

  • A phase I study examining the combination of ramucirumab with pembrolizumab in NSCLC, gastric cancer and bladder cancer;

  • A phase I study examining the combination of necitumumab with pembrolizumab in NSCLC; and

  • A phase I study examining the combination of abemaciclib, a CDK 4 and 6 inhibitor, with pembrolizumab. Based on the phase I trial results, the collaboration has the potential to progress top Phase II trials in patients who have been diagnosed with either metastatic breast cancer or NSCLC.

Table of Contents

YOU MAY BE INTERESTED IN

Secretary of the U.S. Department of Health and Human Services Robert F. Kennedy Jr. appeared before the House Energy and Commerce Subcommittee on Health to defend the HHS fiscal year 2026 budget proposal, and faced criticism from several Democratic lawmakers on what they described as a lack of transparency and scientific rigor in the agency’s recent decisions.

The full-scale Russian invasion of Ukraine has devastated the Ukrainian healthcare infrastructure, disrupting cancer care, halting clinical trials, and compounding long-standing systemic challenges.  Even before the war, Ukraine’s oncology system faced major constraints: Limited access to radiotherapy equipment, outdated chemotherapy supply chains, and workforce shortages. The invasion intensified these issues—cancer hospitals were damaged, warehouses destroyed,...

Patients affected by cancer are increasingly turning to artificial intelligence-powered chatbots, such as ChatGPT and Gemini, for answers to pressing health questions. These tools, available around the clock and free from geographic or scheduling constraints, are appealing when access to medical professionals is limited by financial, language, logistical, or emotional barriers. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login